These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576 [TBL] [Abstract][Full Text] [Related]
3. [Proton beam therapy with concurrent chemotherapy for non-small cell lung cancer -- our experiences and future direction]. Niho S; Motegi A; Akimoto T Gan To Kagaku Ryoho; 2015 Feb; 42(2):144-7. PubMed ID: 25743132 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953 [TBL] [Abstract][Full Text] [Related]
5. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687 [TBL] [Abstract][Full Text] [Related]
7. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546 [TBL] [Abstract][Full Text] [Related]
8. Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer. Takada A; Nakamura T; Takayama K; Makita C; Suzuki M; Azami Y; Kato T; Tsukiyama I; Hareyama M; Kikuchi Y; Daimon T; Toyomasu Y; Ii N; Nomoto Y; Sakuma H; Fuwa N Cancer Med; 2016 Mar; 5(3):506-15. PubMed ID: 26806272 [TBL] [Abstract][Full Text] [Related]
9. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer. Colaco RJ; Huh S; Nichols RC; Morris CG; D'Agostino H; Flampouri S; Li Z; Pham DC; Bajwa AA; Hoppe BS Acta Oncol; 2013 Apr; 52(3):506-13. PubMed ID: 23438357 [TBL] [Abstract][Full Text] [Related]
10. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243 [TBL] [Abstract][Full Text] [Related]